AMGEN INC.
Symbol: AMGN Exchange: NASDAQ Close: 57.58 1-WK % Chg: -0.7%
Business Overview
Amgen Inc., incorporated in 1980, is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products in the areas of hematology, oncology and inflammation. The products include EPOGEN (Epoetin alfa), Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim) and ENBREL (etanercept), which is marketed under a co-promotion agreement with Wyeth. Other products include Kineret (anakinra) and Stemgen (Ancestim). It maintains a sales and marketing force in the United States, Europe, Canada, Australia and New Zealand. In addition, Amgen has entered into licensing and/or co-promotion agreements to market certain of its products, including Aranesp, Neulasta, NEUPOGEN and ENBREL in certain geographic areas outside of the United States. In August 2004, the Company acquired Tularik Inc., a company engaged in drug discovery-related to cell signaling and the control of gene expression.
[GRAPHIC OMITTED]
COPYRIGHT 2004 CBJ, L.P.
COPYRIGHT 2004 Gale Group
Home
A
8-Hour Bayer
